Quality of life and multiple sclerosis;Calidad de vida y esclerosis múltiple

Revista de Neurologia

Volumn 51, Issue 5, 2010, Pages 279-288

  Olascoaga, Javier ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

Health related quality of life; Multiple sclerosis; Physical functioning; Psychological functioning; Quality of life; Quality of life questionnaire; Social functioning; Treatment

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; IMMUNOLOGIC FACTOR;

ANXIETY; BLADDER DYSFUNCTION; COGNITIVE DEFECT; COPING BEHAVIOR; DEPRESSION; EXPANDED DISABILITY STATUS SCALE; FATIGUE; HUMAN; MULTIPLE SCLEROSIS; PAIN; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; ADAPTIVE BEHAVIOR; CLINICAL TRIAL (TOPIC); HEALTH STATUS; PATHOPHYSIOLOGY; PSYCHOLOGY; SOCIAL BEHAVIOR;

ADAPTATION, PSYCHOLOGICAL; CLINICAL TRIALS AS TOPIC; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUESTIONNAIRES; SOCIAL BEHAVIOR;

EID: 77956391588     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5105.2010277     Document Type: Review

References (88)

1. The WHOQoL Group. Development of the WHOQoL: rationale and current status. Int J Mental Health 1994; 23: 24-56.
2. Minayo MC, Hartz ZM, Buss PM. Quality of life and health: a necessary debate. Ciencia & Saúde Colectiva 2000; 5: 7-18.
3. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835-40.
4. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49: 1237-42.
5. Hincapié-Zapata ME, Suárez-Escudero JC, Pineda-Tamayo R, Anaya JM. Calidad de vida en esclerosis múltiple y otras enfermedades crónicas autoinmunes y no autoinmunes. Rev Neurol 2009; 48: 225-30.
6. Mitchell AJ, Benito-León J, González JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005; 4: 556-66.
7. Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007; 10: 54-60.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
9. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
10. Ayuso-Mateos JL, Lasa L, Vazquez-Barquero JL, Oviedo A, Díez-Manrique JF. Measuring health status in psychiatric community surveys: internal and external validity of the Spanish version of the SF-36. Acta Psychiatr Scand 1999; 99: 26-32. (Pubitemid 29071169)
11. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
12. Ware JE Jr. SF-36 health survey update. Spine 2000; 25: 3130-9.
13. Aymerich M, Guillamón I, Perkal H, Nos C, Porcel J, Berra S, et al. Adaptación al español del cuestionario específico MSQOL-54 para pacientes con esclerosis múltiple. Neurología 2006; 21: 181-7.
14. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206.
15. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 2005; 231: 29-34.
16. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003; 9: 63-72.
17. Hernández MA. Tratamiento de la esclerosis múltiple y calidad de vida. Rev Neurol 2000; 30: 1242-5.
18. Modrego PJ, Pina MA, Simón A, Azuara MC. The interrelations between disability and quality of life in patients with multiple sclerosis in the area of Bajo Aragón, Spain: a geographically based survey. Neurorehabil Neural Repair 2001; 15: 69-73. (Pubitemid 32800197)
19. Heesen C, Bohm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008; 14: 988-91.
20. Delgado-Mendilívar JM, Cadenas-Díaz JC, Fernández-Torrico JM, Navarro-Mascarell G, Izquierdo G. Estudio de la calidad de vida en la esclerosis múltiple. Rev Neurol 2005; 41: 257-62.
21. Shawaryn MA, Schiaffino KM, LaRocca NG, Johnston MV. Determinants of health-related quality of life in multiple sclerosis: the role of illness intrusiveness. Mult Scler 2002; 8: 310-8.
22. Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, et al. Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. Arch Neurol 2004; 61: 679-86.
23. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004; 97: 671-6.
24. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984; 65: 135-8.
25. Krupp LB, Álvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988; 45: 435-7.
26. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-3.
27. Monks J. Experiencing symptoms in chronic illness: fatigue in multiple sclerosis. Int Disabil Stud 1989; 11: 78-83. (Pubitemid 20142067)
28. Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler 2005; 11: 602-9.
29. Merkelbach S, Sittinger H, Koenig J. Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis? J Nerv Ment Dis 2002; 190: 388-93.
30. Bermejo PE, Oreja-Guevara C, Díez-Tejedor E. El dolor en la esclerosis múltiple: prevalencia, mecanismos, tipos y tratamiento. Rev Neurol 2010; 50: 101-8.
31. Grasso MG, Clemenzi A, Tonini A, Pace L, Casillo P, Cuccaro A, et al. Pain in multiple sclerosis: a clinical and instrumental approach. Mult Scler 2008; 14: 506-13.
32. Brochet B, Deloire MS, Ouallet JC, Salort E, Bonnet M, Jove J, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study. Clin J Pain 2009; 25: 211-7.
33. Khan F, Pallant J. Chronic pain in multiple sclerosis: prevalence, characteristics, and impact on quality of life in an Australian community cohort. J Pain 2007; 8: 614-23. (Pubitemid 47198553)
34. Newland PK, Naismith RT, Ullione M. The impact of pain and other symptoms on quality of life in women with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2009; 41: 322-8.
35. Nortvedt MW, Riise T, Myhr KM, Landtblom AM, Bakke A, Nyland HI. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 2001; 7: 231-5.
36. Nortvedt MW, Riise T, Frugard J, Mohn J, Bakke A, Skar AB, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007; 13: 106-12.
37. D'Alisa S, Miscio G, Baudo S, Simone A, Tesio L, Mauro A. Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil 2006; 28: 307-14. (Pubitemid 43307417)
38. Fruehwald S, Loeffler-Stastka H, Eher R, Saletu B, Baumhackl U. Depression and quality of life in multiple sclerosis. Acta Neurol Scand 2001; 104: 257-61.
39. Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klosch G, Kollegger H, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004; 110: 6-13.
40. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci 2002; 205: 51-8. (Pubitemid 36158993)
41. Janssens AC, Van Doorn PA, De Boer JB, Kalkers NF, Van der Meche FG, Passchier J, et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler 2003; 9: 397-403.
42. Arnett PA, Barwick FH, Beeney JE. Depression in multiple sclerosis: review and theoretical proposal. J Int Neuro psychol Soc 2008; 14: 691-724.
43. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009; 277: S37-41.
44. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005; 11: 328-37.
45. Brassington JC, Marsh NV. Neuropsychological aspects of multiple sclerosis. Neuropsychol Rev 1998; 8: 43-77.
46. Paes RA, Alvarenga RM, Vasconcelos CC, Negreiros MA, Landeira- Fernández J. Neuropsicología de la esclerosis múltiple primaria progresiva. Rev Neurol 2009; 49: 343-8.
47. Ryan L, Clark CM, Klonoff H, Li D, Paty D. Patterns of cognitive impairment in relapsing-remitting multiple sclerosis and their relationship to neuropathology on magnetic resonance images. Neuropsychol 1996; 10: 176-93.
48. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001; 7: 340-4. (Pubitemid 33026260)
49. Higginson CI, Arnett PA, Voss WD. The ecological validity of clinical tests of memory and attention in multiple sclerosis. Arch Clin Neuropsychol 2000; 15: 185-204.
50. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991; 41: 692-6.
51. O'Connor P, Lee L, Ng PT, Narayana P, Wolinsky JS. Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology 2001; 57: 889-91.
52. Benito-León J, Morales JM, Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002; 9: 497-502. (Pubitemid 35013875)
53. Gerbaud L, Deffond D, Mulliez A, Benausse F, Vernay D, Clavelou P. Cognitive impairment and quality of life in multiple sclerosis patients. Rev Neurol (Paris) 2006; 162: 970-9.
54. Goretti B, Portaccio E, Zipoli V, Hakiki B, Siracusa G, Sorbi S, et al. Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. Neurol Sci 2009; 30: 15-20.
55. Montel SR, Bungener C. Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis. Mult Scler 2007; 13: 393-401.
56. Rivera-Navarro J, Morales-González JM, Benito-León J, Mitchell AJ. Dimensión social y familiar: experiencias de cuidadores y personas con esclerosis múltiple. Estudio GEDMA. Rev Neurol 2008; 47: 281-5.
57. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997; 48: 74-80. (Pubitemid 27039520)
58. Aymerich M, Guillamón I, Jovell AJ. Health-related quality of life assessment in people with multiple sclerosis and their family caregivers. A multicenter study in Catalonia (Southern Europe). Patient Prefer Adherence 2009; 3: 311-21.
59. Patti F, Pozzilli C, Montanari E, Pappalardo A, Piazza L, Levi A, et al. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 783-91.
60. Foley JF, Brandes DW. Redefining functionality and treatment efficacy in multiple sclerosis. Neurology 2009; 72: S1-11.
61. Hernández-Pérez MA. Seguridad y tolerabilidad en la fase inicial del tratamiento con interferón beta-1a 44 microgramos en pauta lenta frente a pauta rápida en pacientes con esclerosis múltiple (estudio PARALEN). Rev Neurol 2009; 48: 505-8.
62. Patrucco L, Rojas JI, Cristiano E. Efecto del tratamiento a largo plazo con interferón beta en la gravedad de la esclerosis múltiple remitente-recurrente. Rev Neurol 2010; 50: 529-32.
63. Río-Izquierdo J, Montalban X. Natalizumab en esclerosis múltiple. Rev Neurol 2009; 49: 265-9.
64. Sánchez-Soliño O, Arroyo E, Grau C, Parra JC, You X, on behalf of the Spanish GAO study group. Quality of life in patients with relapsing-remitting multiple sclerosis treated with immunomodulators: 2 years results in Spain. 25th Congress of ECTRIMS. Düsseldorf, Alemania, septiembre de 2009.
65. De Sèze J, Borgel F, Brudon F. Immunomodulator treatments and multiple sclerosis: compliance and factors of adherence to treatment. Mult Scler 2007; 13: S46.
66. Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, et al. Interferon-beta 1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 2001; 57: 1870-5.
67. Miller M. Assessing the effects of IFNb-1a on health related quality of life in secondary-progressive MS patients: results from the IMPACT study. 54th AAN Meeting. Denver, EE.UU., abril de 2002.
68. Vermersch P, De Sèze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis: influence of interferon-beta 1a (Avonex) treatment. Mult Scler 2002; 8: 377-81.
69. Putzki N, Fischer J, Gottwald K, Reifschneider G, Ries S, Siever A, et al. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol 2009; 16: 713-20.
70. Isaksson AK, Ahlstrom G, Gunnarsson LG. Quality of life and impairment in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 64-9. (Pubitemid 40017186)
71. Lily O, McFadden E, Hensor E, Johnson M, Ford H. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler 2006; 12: 808-13.
72. Mohr DC, Likosky W, Dwyer P, Van der Wende J, Boudewyn AC, Goodkin DE. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol 1999; 56: 1263-5.
73. Goeb JL, Even C, Nicolas G, Gohier B, Dubas F, Garre JB. Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry 2006; 21: 186-93.
74. Simone IL, Ceccarelli A, Tortorella C, Bellacosa A, Pellegrini F, Plasmati I, et al. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes 2006; 4: 96.
75. Tsai SJ. Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Med Hypotheses 2007; 69: 145-8.
76. Ziemssen T, Reichmann H, Schneider H. Presence of glatiramer acetatespecific TH2 cells in the cerebrospinal fluid of patients with multiple sclerosis 12 months after the start of therapy with glatiramer acetate. J Neurodegen Regen 2008; 1: 19-22.
77. Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 2004; 75: 1045-7.
78. Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 2008; 6: 67.
79. Jongen PJH, Carton H, Sanders EACM, Seeldrayers P, Fredrikson S, Andersson M, et al, the FOCUS Study Group. FOCUS study: fatigue and quality of life in relapsing-remitting multiple sclerosis patients using glatiramer acetate improved at 6 and 12 months of treatment. 23rd Congress of ECTRIMS. Praga, República Checa, octubre de 2007.
80. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008; 6: 100.
81. Shvarts PG, Zavalishin IA. Influence of 5-year glatiramer acetate therapy on prevalence of lower urinary tract dysfunction in relapsing-remitting multiple sclerosis. Mult Scler 2008; 14: S159-60.
82. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62: 335-46.
83. Sastre-Garriga J, Galán-Cartañá I, Montalban X, Thompson A. Neurorrehabilitación en esclerosis múltiple. Neurología 2005; 20: 245-54.
84. Solari A, Filippini G, Gasco P, Colla L, Salmaggi A, La Mantia L, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999; 52: 57-62.
85. Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 1999; 52: 50-6.
86. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 2002; 8: 161-8. (Pubitemid 34256754)
87. Stroud NM, Minahan CL. The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis. Health Qual Life Outcomes 2009; 7: 68.
88. Romberg A, Virtanen A, Ruutiainen J. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. J Neurol 2005; 252: 839-45.